The FDA recently approved tremelimumab, an anti-CTLA-4 mAB, in combination with durvalumab, an anti-PD-L1 mAB, for unresectable HCC after data was evaluated in the HIMALAYA phase III trial, which showed that the combination therapy was associated with a significantly higher OS when compared to sorafenib alone (stratified HR 0.78, p < 0.01), reduced the risk by 22% in patients with stage III-IV unresectable HCC when compared to sorafenib alone [236]. This evidence concerns the gene CD274 and hepatocellular carcinoma.